business

Insilico Medicine Considers Secondary Listing in Abu Dhabi

26 Mayıs 2026Bloomberg

Insilico Medicine Cayman TopCo, a biotech firm listed in Hong Kong, is reportedly exploring a secondary listing in Abu Dhabi. This potential move could mark a significant milestone as it would be the first instance of a company from outside the Gulf region listing shares on a local exchange.
The discussions are still in the early stages, with no final decisions made yet.
The UAE has been actively trying to diversify its economy and attract foreign investments, particularly in sectors like biotechnology. Insilico's interest in a UAE listing aligns with these broader economic goals and could pave the way for more international firms to consider similar moves.
The potential listing of Insilico in Abu Dhabi reflects a growing trend of international companies seeking to tap into the Gulf's capital markets. This move could enhance the region's reputation as a hub for biotech investments and attract further foreign interest.

NewsAI özeti

This article is based on information from sources familiar with the matter and has not been officially confirmed by Insilico Medicine.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.